By Ben Glickman
Shares of Lumos Pharma soared on Tuesday after the company said its hormone deficiency treatment met all of its endpoints in a trial.
The stock rose 117% to $7.91 at 5:35 pm. ET in post-market trading, which followed a 4% rise at Tuesday’s close. Shares are up 0.8% this year.
The Austin, Texas-based pharmaceutical company said its Phase 2 trial of LUM-201 in pediatric growth hormone deficiency patients showed that its treatment could be a viable alternative to injectable hormone deficiency therapies.
The company’s Phase 2 dose-finding trial and Phase 2 pharmacokinetic/pharmacodynamic trial met all of their primary and secondary endpoints.
Lumos said a 1.6 milligram per kilogram dose of LUM-201 led to a growth rate comparable to that of the moderate PGHD population.
The company will meet with the Food and Drug Administration in the first quarter of 2024 and finalize plans for a Phase 3 trial.
Write to Ben Glickman at ben.glickman@wsj.com
Read the full article here
